Neulasta® is given as a subcutaneous (under the skin) injection and comes in prefilled syringes. The recommended dose of Neulasta® is a prefilled syringe (6 mg) once per chemotherapy cycle. Neulasta® should not be given to infants, children, or adolescents weighing less than 45 kilograms.
How are patients typically monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Neulasta®. Typically, blood will be drawn to check levels of white blood cells.
Patients may also undergo physical examinations, scans or other measures to assess side effects and response to therapy. What are the common (occur in 30% or more of patients) side effects of treatment with Neulasta®? There are no known common side effects attributable to Neulasta®.
What are the less common (occur in 10% to 29% of patients) side effects of treatment with Neulasta®? €¢ Bone pain • Changes in some laboratory tests, which tend to normalize following treatment • ... more.
I cant really gove you an answer,but what I can give you is a way to a solution, that is you have to find the anglde that you relate to or peaks your interest. A good paper is one that people get drawn into because it reaches them ln some way.As for me WW11 to me, I think of the holocaust and the effect it had on the survivors, their families and those who stood by and did nothing until it was too late.